Media coverage about Atara Biotherapeutics (NASDAQ:ATRA) has been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atara Biotherapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.9396635285548 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Atara Biotherapeutics (NASDAQ ATRA) traded up 2.16% on Friday, hitting $16.55. The stock had a trading volume of 207,711 shares. The company’s market cap is $505.75 million. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00. The stock’s 50-day moving average price is $14.71 and its 200 day moving average price is $15.84.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05). On average, analysts predict that Atara Biotherapeutics will post ($3.89) EPS for the current year.

A number of equities research analysts have issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a research report on Monday, September 11th. ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Finally, BidaskClub lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $25.50.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Given Daily Media Impact Rating of 0.19” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/atara-biotherapeutics-atra-given-daily-media-impact-rating-of-0-19/1599491.html.

In related news, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $13.54, for a total value of $59,576.00. Following the completion of the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at approximately $9,989,365.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $14.92, for a total value of $89,520.00. Following the completion of the sale, the executive vice president now owns 362,080 shares of the company’s stock, valued at $5,402,233.60. The disclosure for this sale can be found here. Insiders have sold a total of 53,909 shares of company stock valued at $810,518 over the last quarter. 16.10% of the stock is currently owned by corporate insiders.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.